Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies

Neurobiology of Disease

Volumn 34, Issue 3, 2009, Pages 484-486

  Parnetti, L ^a   Balducci, C ^a   Pierguidi, L ^a,b   De Carlo, C ^a,b   Peducci, M ^a,b   D'Amore, C ^a,b   Padiglioni, C ^a   Mastrocola, S ^a,b   Persichetti, E ^a   Paciotti, S ^a   Bellomo, G ^c   Tambasco, N ^a   Rossi, A ^a   Beccari, T ^a   Calabresi, P ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c Ospedale S Giovanni Battista   (Italy)

Author keywords

mannosidase; glucocerebrosidase; Alzheimer's Disease; Cerebrospinal fluid; Dementia with Lewy Bodies; Fronto Temporal Dementia; Lysosomal enzymes; Lysosomal hydrolases; Synucleinopathies

Indexed keywords

ALPHA MANNOSIDASE; BETA GALACTOSIDASE; BETA GLUCOCEREBROSIDASE; BETA MANNOSIDASE; BETA N ACETYLHEXOSAMINIDASE; BIOLOGICAL MARKER; GLUCOSYLCERAMIDASE; HYDROLASE; SYNUCLEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; ENZYME ACTIVITY; ENZYME SPECIFICITY; FEMALE; FRONTOTEMPORAL DEMENTIA; GENETIC RISK; HUMAN; LEWY BODY; LYSOSOME MEMBRANE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RISK FACTOR; SYNUCLEINOPATHY;

AGED; ALPHA-MANNOSIDASE; ALZHEIMER DISEASE; BETA-GALACTOSIDASE; BETA-MANNOSIDASE; BETA-N-ACETYLHEXOSAMINIDASES; DEMENTIA; FEMALE; GLUCOSYLCERAMIDASE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED;

EID: 67349254635     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.03.002     Document Type: Article

References (22)

1. Anonymous, and The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J. Neurol. Neurosurg. Psychiatry 57 (1994) 416-418
2. Balducci C., Pierguidi L., Persichetti E., Parnetti L., Sbaragli M., Tassi C., Orlacchio A., Calabresi P., Beccari T., and Rossi A. Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov. Disord. 22 (2007) 1481-1484
3. Chu Y., and Kordower J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?. Neurobiol. Dis 25 (2007) 134-149
4. Clark L.N., Ross B.M., Wang Y., Mejia-Santana H., Harris J., Louis E.D., Cote L.J., Andrews H., Fahn S., Waters C., Ford B., Frucht S., Ottman R., and Marder K. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 69 (2007) 1270-1277
5. Eblan M.J., Scholz S., Stubblefield B., Gutti U., Goker-Alpan O., Hruska K.S., Singleton A.B., and Sidransky E. Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism. Neurosci. Lett. 404 (2006) 163-165
6. Goker-Alpan O., Giasson B.I., Eblan M.J., Nguyen J., Hurtig H.I., Lee V.M.-Y., Trojanowski J.Q., and Sidransky E. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 67 (2006) 908-910
7. Goker-Alpan O., Lopez G., Vithayathil J., Davis J., Hallet M., and Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch. Neurol. 65 10 (2008) 1353-1357
8. Hruska K.S., Goker-Alpan O., and Sidransky E. Gaucher disease and the synucleinopathies. J. Biomed. Biotechnol. 2006 (2006) 1-6
9. Jellinger K.A. Pathological substrate of dementia in Parkinson's disease-its relation to DLB and DLBD. Parkinsonism Relat. Disord. 12 (2006) 119-120
10. Lee H.J., Khoshaghideh F., Patel S., and Lee S.J. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci 24 (2004) 1888-1896
11. Lim F., Hernández F., Lucas J.J., Gomez-Ramos P., Moran M.A., and Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol. Cell Neurosci. 18 (2001) 702-714
12. Litvan I., MacIntyre A., Goetz C.G., Wenning G.K., Jellinger K., and Verny M. Accuracy of the clinical diagnosis of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch. Neurol. 55 (1998) 969-978
13. Lopez O.L., Becker J.T., Kaufer D.I., Hamilton R.L., Sweet R.A., Klunk W., and DeKosky S.T. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch. Neurol. 59 (2002) 43-46
14. Martinez-Vicente M., and Cuervo A.M. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol. 6 (2007) 352-361
15. Mata I.F., Samii A., Schneer S.H., Roberts J.W., Griffith A., Leis B.C., Schellenberg G.D., Sidransky E., Bird T.D., Leverenz J.B., Tsuang D., and Zabetian C.P. Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch. Neurol. 65 (2008) 379-382
16. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., and Hansen L.A. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47 (1996) 1113-1124
17. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
18. Nichols W.C., Pankratz N., Marek D.K., Pauciulo M.W., Elsaesser V.E., Halter C.A., Rudolph A., Wojcieszek J., Pfeiffer R.F., and Foroud T. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72 (2009) 310-316
19. Shacka J.J., Roth K.A., and Zhang J. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front. Biosci. 13 (2008) 718-736
20. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol. Genet. Metab. 83 (2004) 6-15
21. Tayebi N., Walker J., Stubblefield B., Orvisky E., LaMarca M.E., Wong K., Rosenbaum H., Schiffmann R., Bembi B., and Sidransky E. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?. Mol. Genet. Metab. 79 (2003) 104-109
22. Tsuboi Y., and Dickson D.W. Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?. Parkinsonism Relat. Disord. 11 (2005) S47-S51